Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698885 | Clinical Oncology | 2013 | 25 Pages |
Abstract
Docetaxel-based chemotherapy remains the standard of care in men with mCRPC who are candidates for palliative systemic therapy. Promising results are emerging with sipuleucel-T and abiraterone in the pre-docetaxel setting and cabazitaxel, abiraterone and enzalutamide in patients who progress on or after docetaxel. Further research to determine the optimal choice, sequence or even the combination of these agents is necessary.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D.A. Loblaw, C. Walker-Dilks, E. Winquist, S.J. Hotte, Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care,